SCHEMBL13532237

SCHEMBL13532237

CCCCOC[C@H]1O[C@@H](c2ccc3c(N(C)C)ncnn23)[C@](C)(OCCCC)[C@@H]1OCCCC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11924463 0.89 DOT1L (0.30) —
SCHEMBL9912348 0.89 DOT1L (0.30) —
SCHEMBL14140990 0.88 — —
SCHEMBL14140989 0.88 — —
SCHEMBL9912333 0.80 — —
SCHEMBL12306914 0.79 — —
SCHEMBL9912351 0.78 — —
SCHEMBL13392125 0.78 — —
SCHEMBL10100148 0.77 — —
SCHEMBL10100412 0.77 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8440813-B2 Antiviral nucleoside analogs BIOCRYST PHARMACEUTICALS, INC. (US) 2013-05-14 — — US disclosed
US-20100015094-A1 ANTIVIRAL NUCLEOSIDE ANALOGS WILMINGTON TRUST, NATIONAL ASSOCIATION 2010-01-21 — — US disclosed
Send feedback